| Clopidogrel: a CURE in acute coronary syndromes? | |
| | |
MedLine Citation:
|
PMID: 11866684 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The standard approach to preventing acute coronary syndromes (ACSs)has been to inhibit platelet aggregation with aspirin and to inhibit blood coagulation with low molecular-weight heparin (LMWH). Even with this combination there is still a substantial short and long-term cardiovascular risk. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial [1] compared clopidogrel plus aspirin against aspirin alone in patients with ACSs. The clopidogrel regimen was a loading dose of 300 mg p.o. followed by 75 mg/day and the recommended dose of aspirin was 75 - 325 mg/day. The first primary outcome was a composite of death from cardiovascular causes, non-fatal myocardial infarction (MI) or stroke and this occurred significantly less often in the clopidogrel than the placebo group (9.3 vs. 11.4%). Although there were more clopidogrel patients with life-threatening bleeding (clopidogrel 2.2%, placebo 1.8%), this represented GI haemorrhages and bleeding at sites of arterial puncture rather than fatal bleeding. This trial suggests a role for clopidogrel in the long-term treatment of ACSs. |
| | |
Authors:
|
Sheila A Doggrell |
Related Documents
:
|
18852594 - Drug-eluting stents in a patient with favism: is the aspirin administration safe? 12143264 - Clopidogrel and acute coronary syndrome. 14551514 - The management of unstable angina and non-st-segment elevation myocardial infartion. 12208224 - Platelet glycoprotein iib/iiia inhibition in acute coronary syndromes. gradient of bene... 6448134 - Hypocalcemic cardiomyopathy. 22016304 - The characteristics of verapamil-sensitive idiopathic left ventricular tachycardia comb... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 3 ISSN: 1465-6566 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2002 Mar |
Date Detail:
|
Created Date: 2002-02-27 Completed Date: 2002-09-20 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 351-3 Citation Subset: IM |
Affiliation:
|
Department of Physiology and Pharmacology, University of Queensland, Brisbane, Queensland 4072, Australia. s_doggrell@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Aged Aspirin / therapeutic use Coronary Disease / drug therapy*, mortality Double-Blind Method Female Hemorrhage / chemically induced Humans Male Middle Aged Myocardial Infarction / drug therapy, mortality Platelet Aggregation Inhibitors / administration & dosage, adverse effects, therapeutic use* Stroke / drug therapy, mortality Ticlopidine / administration & dosage, adverse effects, analogs & derivatives, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Seretide for obstructive lung disease.
Next Document: Future developments in assisted reproduction in humans.